Time injections strategically (evenings before days off)
The SUSTAIN 6 trial examined semaglutide in people with established cardiovascular disease and found no increase in hypoglycemic events compared to control groups
Gastrointestinal adverse effects are the most frequently reported and include: Nausea (very common): typically most pronounced during treatment initiation and dose escalation, often improving with continued use Diarrhoea and vomiting (very common): may contribute to dehydration risk and electrolyte disturbances if severe or prolonged Constipation (common): can alternate with diarrhoea
Expert Knowledge on GLP-1 and GIP Medications: Unlock insider insights into the fastest-growing trend in fitness and healthcare
The product does NOT contain prescription GLP-1 medications such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound)
Julian Lagoy, MD, board-certified psychiatrist with Mindpath Health Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice